Fourth Industrial Revolution

Scientists identify a potential new treatment for melanoma

"Umbrellas", the sculpture by Giorgos Zogolopoulos is illuminated in pink light to mark Breast Cancer Awareness Month in Thessaloniki in northern Greece October 21, 2014. REUTERS/Alexandros Avramidis (GREECE - Tags: HEALTH SOCIETY TPX IMAGES OF THE DAY)

"Umbrellas", the sculpture by Giorgos Zogolopoulos is illuminated in pink. Image: REUTERS/Alexandros Avramidis

Ziba Kashef
Senior Writer, Editor and Communications Consultant, Yale University Office of Public Affairs and Communications
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on Fourth Industrial Revolution?
The Big Picture
Explore and monitor how Fourth Industrial Revolution is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Fourth Industrial Revolution

Yale Cancer Center researchers have identified a gene in melanoma that can dramatically affect the growth of the disease. The findings, published in the journal Cell Reports, provide new insight into how melanoma grows and identifies a new target for treatment of melanoma and other cancers.

Enzymes that chemically modify DNA, known as DNA methyltranferases, play critical roles in regulating gene expression during development, but their role in cancer formation is less clear. The new Yale study has uncovered a novel role for a specific DNA methyltransfearase enzyme — DNMT3B — in regulating melanoma growth.

Abnormally high expression of DNA methyltransferases is common in cancers, including melanoma. High expression of DNA methyltransferases can inappropriately switch genes off or on, which can contribute to tumor formation and growth. However, little is known about the specific growth-signaling pathways affected by DNA methyltransferase enzymes like DNMT3B. Yale researchers identified a specific cell-signaling pathway that is dependent on DNMT3B. They found that reducing DNMT3B delayed melanoma formation in mice by affecting mTORC2, a protein complex that is important for controlling cell growth, size, and survival.

“We have identified a new target for drug development as well as a new way of targeting an existing pathway. These findings identify DNMT3B as an attractive target for cancer therapy,” said Dr. Marcus W. Bosenberg, associate professor of dermatology and pathology at Yale School of Medicine, and senior author on the study.

Malignant melanoma is the most deadly form of skin cancer, accounting for 80% of all skin cancer deaths. The research, published early online by Cell Reports, could lead to development of new strategies to slow melanoma growth by targeting DNMT3B, say the researchers.

All authors are from Yale; they are Goran Micevic, Viswanathan Muthusamy, William Damsky, Nicholas Theodosakis, Xiaoni Liu, Katrina Meeth, and Dr. Manjula Santhanakrishnan.

The Sokoloff Family-Melanoma Research Alliance Team Science Award, Yale Cancer Center, National Cancer Institute, and Joanna M. Nicolay Melanoma Foundation funded the study.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Generative AI is rapidly evolving: How governments can keep pace

Karla Yee Amezaga, Rafi Lazerson and Manal Siddiqui

October 11, 2024

About us

Engage with us

  • Sign in
  • Partner with us
  • Become a member
  • Sign up for our press releases
  • Subscribe to our newsletters
  • Contact us

Quick links

Language editions

Privacy Policy & Terms of Service

Sitemap

© 2024 World Economic Forum